Celestra셀레스트라
352770 · KOSDAQ · ₩352770 · 셀레스트라
- Market cap
- ₩14B
- Enterprise value
- ₩16B
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- 175.4%
- Net margin
- 7,387.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range0.0% from the high
₩5,250Today: ₩5,250 – ₩5,250₩5,250
Returns
- 1W0.0%
- 1M0.0%
- 3M0.0%
- 6M0.0%
- YTD0.0%
- 1Y0.0%
- Volume today
- —
- Traded today
- —
- Listed shares
- 2,592,407
- EPS (12 months)
- −₩4,511
- Earnings yield −85.9%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
- MomentumFlat0% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Celestra stock overview
Celestra (셀레스트라, KRX: 352770) is listed on KOSDAQ, in the Biotech & Pharma sector. Clinomics is a Korean company developing and commercializing early cancer and disease diagnosis services based on genome-driven bio-health data processing, liquid biopsy technology that detects circulating tumor cells and cell-free DNA from blood, and multi-omics analysis. Its shares closed at ₩5,250 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩14B.
Key facts
- Market cap
- ₩14B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- Clinomics is a Korean company developing and commercializing early cancer and disease diagnosis services based on genome-driven bio-health data processing, liquid biopsy technology that detects circulating tumor cells and cell-free DNA from blood, and multi-omics analysis.
Quick answers about Celestra
- What does Celestra do?
- Clinomics is a Korean company developing and commercializing early cancer and disease diagnosis services based on genome-driven bio-health data processing, liquid biopsy technology that detects circulating tumor cells and cell-free DNA from blood, and multi-omics analysis. Its offerings include genome-based healthcare tests such as Geno-Test, Geno-D and Geno-Dx, liquid biopsy devices such as CD-Prime and CTC-Solo, cancer diagnosis and monitoring panels such as Cancer-Prime, and multi-omics early diagnosis services for cancers such as colorectal and lung cancer, which are still in development. The company also operates a bio big data center and reports its revenue through bio, food and food service, and investment divisions.
- What is the market cap of Celestra?
- The market capitalisation of Celestra was ₩14B at the close on Oct 27, 2026.
- When is the next earnings report from Celestra?
- Korean companies rarely announce results dates in advance. Based on when Celestra filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Clinomics is a Korean company developing and commercializing early cancer and disease diagnosis services based on genome-driven bio-health data processing, liquid biopsy technology that detects circulating tumor cells and cell-free DNA from blood, and multi-omics analysis. Its offerings include genome-based healthcare tests such as Geno-Test, Geno-D and Geno-Dx, liquid biopsy devices such as CD-Prime and CTC-Solo, cancer diagnosis and monitoring panels such as Cancer-Prime, and multi-omics early diagnosis services for cancers such as colorectal and lung cancer, which are still in development. The company also operates a bio big data center and reports its revenue through bio, food and food service, and investment divisions.
Written by AI from the company's latest annual report.
- Korean name
- 셀레스트라
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 백서현
- Founded
- Jun 2011
- Listed
- Dec 2020
- Listed shares
- 2,592,407
- Fiscal year ends
- Month 12
- Website
- www.clinomics.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Change of Head Office LocationSep 23, 2026
- Market Notice (No Market Measures Yet Taken Regarding Rehabilitation Procedure Termination Decision)Aug 24, 2026
- Decision to Terminate Rehabilitation ProcedureAug 24, 2026
- Other Market Notice (Non-Implementation of Procedures Following Addition of Grounds for Substantive Review of Listing Eligibility)Aug 14, 2026
- Confirmation of Facts Such as Adverse Opinion on Semi-annual Review (Audit), Including Capital Impairment Ratio of 50% or More or Equity Under ₩1BAug 14, 2026
Titles in Korean until English translations are added.
Also known as: Celestra / 셀레스트라 / 352770 / KRX:352770
Source: KRX statistical information